Fredun Pharma Peer Comparison

BSE: 539730

₹1,477.70

₹15.60 (1.07%)

As on 16-Oct-2026IST

Market cap

₹2,523 Cr

Revenue (TTM)

₹748 Cr

P/E Ratio

57.6

P/B Ratio

8.3

Div. Yield

0 %

Edit

	Fredun Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Market cap (₹ Cr)	2,523	31,674	26,307	26,224	25,017
Revenue (₹ Cr)	748	3,564	9,205	1,462	1,936
Net Profit (₹ Cr)	43.82	414.00	-371.81	387.35	288.22
Net Margin (%)	5.86	11.23	-3.93	26.01	14.79
RoE (%)	20.13	8.38	-3.85	25.18	29.77
Price to Earnings	57.58	77.44	--	67.90	86.80
Price-To-Book	8.28	6.29	3.29	15.20	18.64

Income Statement (₹ Cr)

	Fredun Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Operating Revenue	747.52	3,564.00	9,205.28	1,461.80	1,935.80
Total Income	747.52	3,686.00	9,449.59	1,489.25	1,948.58
Total Expenditure	637.23	2,792.00	8,195.15	919.25	1,485.56
EBITDA	110.29	772.00	1,010.13	542.56	450.24
Depreciation	10.40	226.00	857.51	37.68	50.83
EBIT	99.89	546.00	152.62	504.88	399.41
Interest	41.38	217.00	342.73	3.77	40.84
Other Income	0.00	122.00	244.31	27.45	12.78
Exceptional Items	0.00	12.00	-216.88	0.00	0.00
Profit before Tax	58.51	463.00	-162.68	528.56	371.35
Provision for Tax	14.69	49.00	209.13	141.21	83.14
Profit after Tax	43.82	414.00	-371.81	387.35	288.22

	Fredun Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Shareholder's Funds	278.11	4,940.00	8,162.62	1,653.56	1,288.82
Minority Interest	0.00	-5.00	0.00	-1.13	0.00
Non-Current Liabilities	67.11	1,712.00	5,044.14	42.40	202.03
Current Liabilities	296.86	1,622.00	4,758.28	230.82	835.87
Total Liabilities	--	8,578.00	17,723.32	1,983.96	2,326.71

	Fredun Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Non-Current Assets	120.27	5,343.00	10,211.52	1,026.85	519.60
Current Assets	498.17	2,606.00	7,191.66	881.27	1,681.81
Total Assets	--	8,578.00	17,723.32	1,983.96	2,326.71
Total Debt*	--	2,125.00	5,495.48	26.49	259.37
Net Current Assets	201.31	984.00	2,433.38	650.46	845.94
Contingent Liabilities	--	768.26	95.72	17.25	19.09

	Fredun Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Cash From Operating Activities	--	390.00	1,652.60	292.17	205.05
Cash Flow from Investing Activities	--	-241.00	-826.03	-265.94	-409.72
Cash from Financing Activities	--	-54.00	-38.98	4.10	283.07
Net Cash Inflow / Outflow	--	95.00	787.59	30.33	78.39

	Fredun Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
ROCE (%)	--	6.79	1.24	32.42	29.22
ROE (%)	20.13	8.38	-3.85	25.18	29.77
ROA (%)	7.76	4.94	-2.21	21.93	24.77
EBIT Margin (%)	13.36	15.32	1.66	34.54	20.63
Net Margin (%)	5.86	11.23	-3.93	26.01	14.79
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Fredun Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Revenue Growth (%)	50.31	18.37	0.78	40.90	46.65
EBIT Growth (%)	76.98	252.26	-70.53	124.50	62.13
Net Profit Growth (%)	89.55	377.85	-1,383.43	104.15	89.49
EPS Growth (%)	37.58	1,001.33	-484.84	42.32	78.60
Book Value Growth (%)	--	13.47	0.33	26.03	144.31

	Fredun Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Price / Earnings	22.00	79.49	-84.07	67.90	85.46
Price / Book Value	8.28	6.29	3.29	15.20	18.64
Dividend Yield (%)	0.02	0.00	0.00	0.08	0.10
EV/EBITDA	24.30	42.92	30.14	47.97	55.37
Market Cap (₹ Cr)	--	19,071.62	18,108.89	20,944.75	12,753.19

	Fredun Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Debt to Equity	0.20	0.31	0.53	0.02	0.11
Short term debt to equity ratio	--	0.09	0.09	0.02	0.05
Current Ratio	1.68	1.61	1.51	3.82	2.01
Quick Ratio	0.77	1.06	0.87	2.82	1.14
Interest Coverage	2.41	3.13	0.53	141.16	10.09

	Fredun Pharma	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Debtors to sales (%)	12.40	16.50	23.44	24.80	26.28
Asset Turnover	1.32	0.43	0.55	0.83	1.66
Receivable days	--	58.75	78.20	88.98	40.13
Inventory Days	--	75.82	93.30	56.04	60.29
Payable days	--	186.21	226.14	99.95	232.47
Cash Conversion Cycle	--	-51.64	-54.64	45.07	-132.04

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.